HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
"Skip to content\nHome\nProducts\nClinical\nNews\nInvestors\nAbout Us\nContact Us\nINVEST NOW\nNEWS\nHeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone\nMay 29, 2025\n\nMay 29, 2025\n\nSouthlake, TX, May 29, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom.\n\nThis milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month.\n\nWestcliffe Health Innovations provides cardiology services to the U.K. National Health Service (NHS) in the Bradford and Leeds region. As the largest publicly funded healthcare system in the world, the NHS plays a vital role in pioneering access to innovative healthcare technologies. The implementation of MyoVista Insights at Westcliffe is intended to position it as a key reference site for HeartSciences, particularly within the U.K. market.\n\nMyoVista Insights is a cloud-native, next-generation ECG management system built to enhance clinical decision-making and improve healthcare IT efficiency. It is being developed as the first vendor- and device-agnostic ECG platform capable of running AI-ECG algorithm models from multiple partners—streamlining ECG workflows and helping reduce operational costs for healthcare providers.\n\nDr. Matthew Fay, Director of Cardiology at Westcliffe, is a leading figure in bringing cardiology services to the frontlines of healthcare across the U.K. He founded a 27-partner GP super-practice, has contributed to the development of both local and national clinical guidelines, and has led efforts to transition cardiovascular services from hospitals into community settings over the past several years.\n\n“In an area with socio-economic challenges and higher-than-average rates of cardiovascular disease, ensuring easy access to ECGs, the gateway cardiac investigation, is imperative. While healthcare professionals recognize the importance of ECGs, the ability to interpret them varies among generalists. This partnership facilitates easy access to ECGs and provides expert interpretation right in the centre of the community, with results stored in the shared patient record for seamless access.”\n— Dr. Matthew Fay, Clinical Director of Cardiology, Westcliffe Health Innovations, U.K.\n\n“We are thrilled to partner with Dr. Matthew Fay and Westcliffe Health Innovations as the first commercial adopter of MyoVista Insights,” said Andrew Simpson, CEO of HeartSciences. “Dr. Fay and his team have been trailblazers in advancing cardiovascular care across the NHS, and we share a common vision of transforming frontline screening through innovative technology. This agreement represents a pivotal step forward in HeartSciences’ commercial journey and validates our belief in the future of AI-driven ECG management.”\n\nFor more information about MyoVista Insights https://www.heartsciences.com or X: @HeartSciences and for those interested in exploring collaboration or early adoption opportunities, please contact HeartSciences